Dj Chmn Kulkarni Sells 30000 Of Crispr Therapeutics Ag >Crsp

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.

Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.

Shares of Esperion were down in pre-market trading on Nov. 7 owing to the weaker-than-expected results.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

More on ESPR's Q3 Results

Esperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet — that are approved for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.

Product revenues, solely from the United States, totaled $31.1 million in the third quarter, up almost 53% year over year. The upside was driven by continued prescription growth. During the quarter, the drugs’ total retail prescription increased 44% year over year and 12% sequentially.

Product revenues beat the Zacks Consensus Estimate of $29.9 million.

Esperion recorded collaboration revenues, including combined royalty and partner revenues, of $20.5 million during the third quarter, up almost 50% year over year. The upside was driven by increases in royalty sales as well as higher revenues recognized from the litigation-related settlement received from Daiichi Sankyo Europe (DSE),

Collaboration revenues missed the Zacks Consensus Estimate and our model estimate of $25.5 million and $33.2 million, respectively.

Shares of Esperion have plunged 26.1% so far this year compared with the industry’s decline of 3.4%.

Research and development expenses declined 30% from the year-ago period’s levels to $10.4 million, primarily related to the close-out of the company’s CLEAR Outcomes study.

Selling, general and administrative expenses were up 20% year over year to $40 million. The rise was due to an increase in the company’s sales force, in addition to bonus payments and promotional costs.

As of Sept 30, 2024, Esperion had cash, cash equivalents, restricted cash and investment securities of $144.7 million compared with $189.3 million as of June 30, 2024.

2024 Guidance

Esperion reiterated its financial outlook for 2024. The company continues to expect operating expenses in the range of $225-$245 million, including $20 million in non-cash expenses related to stock compensation.

ESPR's Recent Updates

The European Commission approved a label update for Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events in May 2024. Nustendi is a fixed-dose combination of bempedoic acid and ezetimibe.

Hypercholesterolemia indicates elevated levels of cholesterol in the blood.

Following the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering LDL-C, approved for primary and secondary prevention of CV events.

Additionally, the updated labels support the use of Nilemdo and Nustendi either alone or in combination with statins.

Per the company, in the third quarter of 2024, there were more than 23,500 healthcare practitioners writing scripts for Nexletol and Nexlizet.

Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise

Esperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote

ESPR's Zacks Rank & Key Picks

Esperion currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the biotech sector are CRISPR Therapeutics AG CRSP, Lisata Therapeutics, Inc. LSTA and Amicus Therapeutics, Inc. FOLD, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19%.

CRSP’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 100.64%.

In the past 60 days, estimates for Lisata Therapeutics’ 2024 loss per share have narrowed from $2.97 to $2.90. Loss per share estimates for 2025 have narrowed from $2.61 to $2.53 during the same time. Year to date, shares of LSTA have increased 6.9%.

LSTA’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.75%.

In the past 60 days, estimates for Amicus’ 2024 earnings per share have moved up from 21 cents to 22 cents. Earnings per share estimates for 2025 have improved from 50 cents to 53 cents during the same time. Year to date, shares of FOLD have declined 20.8%.

FOLD’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 23.96%.

Zacks Investment Research

Jazz Pharmaceuticals JAZZ reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.

Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.

Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.

The stock fell 9.3% year to date compared with the industry’s 3.5% decline.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

More on JAZZ’s Earnings

Net product sales rose 5% year over year at $989.7 million. The reported figure beat the Zacks Consensus Estimate and our model estimates of $976 million and $971 million, respectively.

Jazz recorded royalty revenues from high-sodium oxybate authorized generic (AG) of $58.2 million, which was twice the figure generated in the year-ago period. While the metric was in line with our model estimates, it beat the Zacks Consensus Estimate of $57 million.

Other royalties and contract revenues rose 47% to $7.1 million in the quarter.

JAZZ’s Neuroscience Segment

Sales of Jazz’s neuroscience products rose 4% to $702.7 million.

Net product sales for the combined oxybate business (Xyrem + Xywav) fell 2% to $446.6 million in the quarter. This combined revenue figure beat the Zacks Consensus Estimate of $431 million and our model estimates of $430 million.

Sales of the sleep disorder drug Xyrem plunged 54% year over year to $58.1 million due to patients switching to Xywav and the launch of AGs last year.

Xywav, a low-sodium formulation of Xyrem, recorded sales of $388.5 million in the quarter, up 17% year over year. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and idiopathic hypersomnia (IH) indications. This drug is currently Jazz’s most extensive product by net sales.

Sales of the epilepsy drug Epidiolex/Epidyolex rose 18% to $251.6 million, likely driven by geographic expansion in ex-U.S. markets. Epidiolex sales beat the Zacks Consensus Estimate and our model estimates of $248 million and $245 million, respectively.

Cannabis-based mouth spray Sativex recorded sales of $4.6 million in the quarter, down 1% year over year.

JAZZ’s Oncology Segment

Oncology product sales increased 9% to $284.8 million.

Chemotherapy drug Rylaze/Enrylaze added sales of $98.8 million in the quarter, down 6% year over year. The drug’s sales were negatively impacted due to a recent update to pediatric acute lymphoblastic leukemia (ALL) protocols regarding the timing of asparaginase administration. Management expects this to affect ongoing demand. The company expects revenues to normalize by early 2025.

Rylaze sales missed the Zacks Consensus Estimate and our model estimates of $114 million and $115 million, respectively.

Zepzelca, approved for small cell lung cancer, recorded sales worth $85.8 million in the quarter, up 10% year over year.

Acute myeloid leukemia drug Vyxeos generated sales of $34.3 million, up 15% from the year-ago period’s levels.

Defitelio sales rose 38% year over year to $65.8 million in the quarter.

Discussion on JAZZ’s Operating Costs

Adjusted selling, general and administrative (SG&A) expenses were up 6% year over year at $288.7 million due to an increase in employee compensation-related expenses.

Adjusted research and development (R&D) expenses down 17% to $181 million, primarily due to a decline in clinical program costs.

JAZZ’s 2024 Guidance

While Jazz reiterated its overall revenue guidance for 2024, the company lowered its revenue prediction for sales in the Oncology franchise.

Total revenues are anticipated to be in the range of $4-$4.1 billion. The Oncology franchise is expected to record sales in the range of $1.08-$1.13 billion, down from the previous guidance of $1.10-$1.15 billion.

Management maintained its revenue prediction for neuroscience sales in the range of $2.83-$2.93 billion. This guidance also includes royalty revenues from high-sodium oxybate AG, which are expected to cross $200 million.

The company also revised its previously issued EPS guidance. Adjusted earnings are now expected to be in the range of $19.50-$20.60 per share, up from the previous guidance of $19.20-$20.30, primarily driven by strategic pipeline prioritization.

While adjusted SG&A expenses are anticipated to be in the range of $1.19-$1.23 billion (maintained), adjusted R&D expenses are expected in the band of $790-$830 million (previously: $810-$850 million).

JAZZ’s Zacks Rank

Jazz currently has a Zacks Rank #3 (Hold).

Jazz Pharmaceuticals PLC Price

Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote

Key Picks Among Biotech Stocks

Some better-ranked stocks from the sector are Amicus Therapeutics FOLD, Biogen BIIB and CRISPR Therapeutics CRSP. While FOLD and CRSP each sports a Zacks Rank #1 (Strong Buy) at present, BIIB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for Amicus Therapeutics’ 2024 EPS have moved up from 21 cents to 22 cents. EPS estimates for 2025 have increased from 49 cents to 53 cents during the same period. Year to date, shares of FOLD have lost 17.3%.

FOLD’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 23.96%.

In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. During the same timeframe, loss estimates for 2025 have improved from $4.98 to $4.94. Year to date, shares of CRSP have lost 19.6%.

CRISPR Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 100.64%.

In the past 60 days, estimates for Biogen’s 2024 EPS have increased from $16.12 to $16.37. EPS estimates for 2025 have improved from $17.09 to $17.15. Year to date, shares of BIIB have lost 31.6%.

Biogen’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 9.99%.

Zacks Investment Research

Amicus Therapeutics FOLD reported third-quarter 2024 adjusted earnings of 10 cents per share, beating the Zacks Consensus Estimate of 8 cents. The company had incurred a loss of 1 cent per share in the year-ago quarter.

The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda.

Revenues in the third quarter totaled $141.5 million, up 37% year over year on a reported basis and 36% on constant-currency (cc) basis. The figure beat the Zacks Consensus Estimate of $134 million. The top line comprised sales of Galafold, which is approved for Fabry disease and Pombiliti + Opfolda.

The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

Despite the better-than-expected results, shares of Amicus were down 4.3% on Nov. 6 following the announcement of the news. The stock has plunged 20.8% so far this year compared with the industry’s decline of 2.5%.

More on FOLD's Q3 Results

In the third quarter, Galafold net product sales were $120.4 million, up 19% year over year at cc, driven by continued strong demand. Galafold sales beat the Zacks Consensus Estimate of $119 million as well as our model estimate of $114.7 million.

Net product sales of Pombiliti + Opfolda were $21.1 million, reflecting sequential growth of 33%. The figure beat the Zacks Consensus Estimate of $18.04 million and our model estimate of $18 million.

Per Amicus, as of the end of October, 203 patients were treated or are scheduled to be treated with the combo drug in five markets (the United States, Germany, the United Kingdom, Spain and Austria).

Total adjusted operating expenses of $82.6 million declined 8% from the year-ago quarter’s figure.

As of Sept 30, 2024, Amicus had cash, cash equivalents and marketable securities worth $249.8 million compared with $260.1 million as of June 30, 2024.

2024 Guidance

Given the strong business performance and continued financial discipline so far, Amicus updated its previously provided guidance for full-year 2024.

The company now expects its total revenues to grow in the range of 30%-32% in 2024 compared with the previously guided range of 26%-31%.

Total Galafold revenues are now expected to grow in the range of 16%-18% compared with the previous guidance of 14%-18%.

This guidance reflects continued patient demand from both switch and treatment-naïve patients, expansion into other geographies, label extensions, continued diagnosis of new Fabry patients and commercial execution across all major markets, including the EU, Japan, the United States and U.K.

For 2024, the company expects total Pombiliti + Opfolda revenue to be in the range of $69-$71 million compared with the earlier projection of $62-$67 million.

The company now anticipates its total adjusted operating expenses in the band of $340-$350 million compared with the previous guidance of $345-$360 million.

The company remains committed to achieving its first full year of non-GAAP profitability in 2024.

FOLD's Recent Updates

Last month, Amicus signed a licensing agreement with Teva Pharmaceuticals TEVA, resolving the patent lawsuit FOLD filed earlier.

The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold (migalastat) 123 mg capsules before the related patents expired.

Per the agreement, Amicus will grant Teva a license to sell its generic version of Galafold in the United States starting Jan. 30, 2037, pending FDA approval and subject to the fulfillment of certain customary conditions.

The agreement ends all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware.

However, a similar patent litigation will continue against Aurobindo Pharma as the remaining active party, and the litigation stay remains in place for Lupin.

Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise

Amicus Therapeutics, Inc. price-consensus-eps-surprise-chart | Amicus Therapeutics, Inc. Quote

FOLD's Zacks Rank & Other Key Picks

Amicus currently carries a Zacks Rank #1 (Strong Buy).

Some other top-ranked stocks from the biotech space are CRISPR Therapeutics AG CRSP and Lisata Therapeutics, Inc. LSTA, each carrying a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19%.

CRSP’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 100.64%.

In the past 60 days, estimates for Lisata Therapeutics’ 2024 loss per share have narrowed from $2.97 to $2.90. Loss per share estimates for 2025 have narrowed from $2.61 to $2.53 during the same time. Year to date, shares of LSTA have increased 6.9%.

LSTA’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.75%.

Zacks Investment Research

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share in the year-ago quarter.

Total revenues, comprising license and collaboration revenues, came in at $14.3 million in the third quarter compared with $17.2 million reported in the year-ago period. The top line missed the Zacks Consensus Estimate of $15 million.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

More on BEAM's Q3 Results

Research and development expenses were $94.3 million in the third quarter, down almost 5.8% from the year-ago quarter’s level.

General and administrative expenses totaled $26.5 million, increasing around 4.3% year over year.

As of Sept 30, 2024, BEAM had cash, cash equivalents and marketable securities worth $925.8 million compared with $1.2 billion as of June 30, 2024. The company expects that its existing cash balance is likely to fund its operating expenses into 2027.

Year to date, shares of Beam Therapeutics have declined 12% compared with the industry’s decrease of 3.8%.

BEAM's Pipeline Updates

The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).

To date, more than 35 patients have been enrolled in the BEACON study investigating BEAM-101 for the treatment of SCD. Of these, eight patients have been dosed with BEAM-101 in the study.

On the third-quarter conference call, management stated that the initial data from the BEACON study supported the potential for meaningful clinical differentiation of BEAM-101 as compared to currently available treatments for SCD.

Per the company, preliminary data as of July 2, 2024, suggested that the initial safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation.

However, one patient died four months after being treated with BEAM-101 due to respiratory failure. The FDA and the Data Safety Monitoring Committee reviewed the case. The patient's death was likely related to busulfan conditioning and was deemed not related to BEAM-101.

This might have impressed investors and resulted in the stock to rise in pre-market trading on Nov. 6.

Detailed data from the study is expected to be presented at a scientific conference later in 2024.

BEAM is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302.

The company has completed dosing in the first cohort of a phase I/II study evaluating BEAM-302 for the treatment of alpha-1 antitrypsin deficiency. Initial clinical data from multiple cohorts of the study is expected in 2025.

BEAM is currently activating sites for the phase I/II study evaluating BEAM-301, an investigational in vivo base editing medicine, for treating glycogen storage disease Type Ia. Patient dosing in the study is expected to begin in 2025 in the United States.

Beam Therapeutics Inc. Price, Consensus and EPS Surprise

Beam Therapeutics Inc. price-consensus-eps-surprise-chart | Beam Therapeutics Inc. Quote

BEAM's Zacks Rank & Key Picks

Beam Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the biotech space are CRISPR Therapeutics AG CRSP, Atea Pharmaceuticals, Inc. AVIR and Amicus Therapeutics, Inc. FOLD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19.5%.

CRSP’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 101.83%.

In the past 60 days, estimates for Atea Pharmaceuticals’ 2024 loss per share have narrowed from $2.55 to $2.22. Loss per share estimates for 2025 have narrowed from $2.58 to $1.80 during the same time. Year to date, shares of AVIR have increased 9.8%.

AVIR’s earnings beat estimates in two of the trailing four quarters while missing on the remaining two occasions, the average surprise being 5.23%.

In the past 60 days, estimates for Amicus’ 2024 earnings per share have moved up from 21 cents to 22 cents. Earnings per share estimates for 2025 have improved from 50 cents to 53 cents during the same time. Year to date, shares of FOLD have declined 17.2%.

FOLD’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 23.96%.

Zacks Investment Research

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share in the year-ago quarter.

Total revenues in the third quarter amounted to $196.8 million and missed the Zacks Consensus Estimate of $199 million. In the year-ago quarter, the company had reported revenues of $110.4 million.

The top line jumped 78.3% year over year, owing to higher sales of Syfovre (pegcetacoplan injection) in the third quarter.

Syfovre was approved for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration by the FDA in February 2023.

Year to date, shares of Apellis have plunged 53.1% compared with the industry’s decline of 3.8%.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

More on APLS' Q3 Results

Revenues in the third quarter included product sales of the marketed drugs — Empaveli (pegcetacoplan) and Syfovre — and licensing and other revenues under the collaboration agreement with Sobi.

Syfovre recorded sales of $152 million in the third quarter, which surged 101.8% year over year, owing to continued strong demand. However, Syfovre's sales missed the Zacks Consensus Estimate of $162 million but slightly beat our model estimate of $151.7 million.

Apellis delivered more than 84,500 commercial vials and nearly 4,000 samples of Syfovre to doctors in the third quarter. As of Sept 30, 2024, the total number of doses of the drug delivered since launch was 420,000.

The potential approval and successful launch of Syfovre in additional geographies will add an incremental stream of revenues to APLS in the future.

Empaveli recorded sales of $24.6 million in the third quarter, up 2.9% from the year-ago quarter’s figure, owing to continued high patient compliance rates of 97%. Empaveli sales were in line with the Zacks Consensus Estimate and beat our model estimate of $23.9 million.

Empaveli is approved in the United States for the treatment of paroxysmal nocturnal hemoglobinuria. The drug is also approved in Europe under the brand name Aspaveli for the same indication.

Licensing and other revenues came in at $20.3 million, up 81.3% year over year.

Research and development expenses increased 11.6% from the prior-year quarter’s level to $88.6 million. This was due to an increase in program-specific external costs and other external costs.

General and administrative expenses totaled $122 million, down 16.2% year over year. This was due to decreases in personnel-related costs, marketing activities, office costs, and professional and consulting fees.

As of Sept 30, 2024, Apellis had cash, cash equivalents and marketable securities worth $396.9 million compared with $360.1 million as of June 30, 2024. APLS expects its cash balance, combined with cash anticipated from sales of marketed products, to be enough to fund its operations in the foreseeable future.

APLS' Recent Pipeline Update

In September 2024, Apellis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency confirmed its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration.

APLS also stated that the CHMP opinion was issued despite broad support for pegcetacoplan from the European retina community and several dissenting votes from CHMP members who had advocated for a path to approval.

In August 2024, Apellis and partner Sobi announced positive top-line data from the phase III VALIANT study evaluating systemic pegcetacoplan in C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN) patients.

Per the data readout, the study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful 68% proteinuria reduction in C3G and IC-MPGN patients treated with pegcetacoplan versus placebo, both in addition to background therapy, at week 26.

Additionally, the study also achieved its key secondary endpoints with statistical significance, whereas nominal significance was observed on the histological endpoint. In the VALIANT study, pegcetacoplan was overall well-tolerated with a consistent safety profile.

Apellis is planning to submit a supplemental new drug application seeking approval for pegcetacoplan in C3G and IC-MPGN in early 2025. A similar regulatory filing by Sobi in the EU is also planned for early 2025.

Apellis Pharmaceuticals, Inc. Price, Consensus and EPS Surprise

Apellis Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Apellis Pharmaceuticals, Inc. Quote

APLS' Zacks Rank

Apellis currently carries a Zacks Rank #3 (Hold).

Key Biotech Picks

Some better-ranked stocks from this space are CRISPR Therapeutics AG CRSP, Atea Pharmaceuticals, Inc. AVIR and Amicus Therapeutics, Inc. FOLD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19.5%.

CRSP’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 101.83%.

In the past 60 days, estimates for Atea Pharmaceuticals’ 2024 loss per share have narrowed from $2.55 to $2.22. Loss per share estimates for 2025 have narrowed from $2.58 to $1.80 during the same time. Year to date, shares of AVIR have increased 9.8%.

AVIR’s earnings beat estimates in two of the trailing four quarters while missing on the remaining two occasions, the average surprise being 5.23%.

In the past 60 days, estimates for Amicus’ 2024 earnings per share have moved up from 21 cents to 22 cents. Earnings per share estimates for 2025 have improved from 50 cents to 53 cents during the same time. Year to date, shares of FOLD have declined 17.2%.

FOLD’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 23.96%.

Zacks Investment Research